Endangered species makes incredible comeback with over 16x population growth: 'We feared it might be the end'
The Sombrero ground lizard was nearing extinction in 2018, with fewer than 100 creatures remaining. However, thanks to efforts by Fauna & Flora, Anguilla National Trust, and Re:wild, the rare lizard species is making a strong comeback.
"In 2018, following yet another severe hurricane, we feared it might be the end for the Sombrero ground lizard," says Farah Mukhida, executive director at Anguilla National Trust, according to Fauna & Flora.
Conservation efforts began in 2021, focusing not only on building up the species count, but also on helping the island's plant life to recover. In only three years, the Sombrero ground lizard population is estimated to be more than 1,600, according to Fauna & Flora.
Sombrero is an uninhabited island located in the Lesser Antilles near Anguilla. Its near-environmental destruction is the result of numerous factors, including mice that had been introduced to the island, former phosphate mining, and hurricane destruction.
Intervention was necessary, as Sombrero is home to many unique creatures.
In addition to homing seabirds, the island alone supports the Sombrero Island wind scorpion, a currently unnamed pygmy gecko, and the Sombrero Island bee. Through the conservation efforts, the mice have been eradicated, according to the report, and native plants — such as seagrape, prickly pear, and sea bean — have been replanted.
In other islands where invasive rodents have damaged the native species population, drones were used to purge rats. But ingenious solutions for rebuilding waning populations don't stop there. When reintroducing endangered eastern quolls, conservationists used a fence to protect them from prey. However, they also placed tunnels that were similar to bathtubs under the fence to allow Eastern long-necked turtles to travel to their water source.
While the restoration of Sombrero Island has helped a tiny creature's species thrive, its scope is more significant.
Conservation efforts like this one are essential to fighting the effects of the planet's rising temperatures. As a result of human-caused polluting gases, animals face changes to the climate and loss of habitat. As the cause of these new dangers to the creatures of the world, it is our responsibility to take action, just like what is being done on Sombrero Island.
Do you think America does a good job of protecting its natural beauty?
Definitely
Only in some areas
No way
I'm not sure
Click your choice to see results and speak your mind.
On LinkedIn, botanist Leigh Fulghum believes that small-scale efforts make the biggest splash. She says, "More success for focused, community-driven conservation. Too many cooks spoil the broth." One Instagram user agreed, writing: "Thank you to dedicated people helping to fix issues that man has created!"
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
2 days ago
- Business Wire
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under 'Events' in the Investors section of the Company's website. Participants may register to join the live call by following the link here to receive the dial-in numbers and unique PIN to access the call. Those who plan on participating are advised to join 15 minutes prior to the start time. A webcast replay of the call will be available on Vistagen's website about 24 hours after the end of the live conference call and will be accessible for at least 30 days. About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists to peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen's neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at


San Francisco Chronicle
3 days ago
- San Francisco Chronicle
What is the summer solstice? An astronomer explains
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Stephen Schneider, UMass Amherst (THE CONVERSATION) The summer solstice marks the official start of summer. It brings the longest day and shortest night of the year for the 88% of Earth's people who live in the Northern Hemisphere. People around the world traditionally observe the change of seasons with bonfires and festivals and Fête de la Musique celebrations. Astronomers can calculate an exact moment for the solstice, when Earth reaches the point in its orbit where the North Pole is angled closest to the Sun. That moment will be at 10:42 p.m. Eastern Time on June 20 this year. In Europe, Africa and points eastward, the moment of the equinox falls on June 21 locally, making that the day of the solstice. From Earth, the Sun will appear farthest north relative to the stars. People living on the Tropic of Cancer, 23.5 degrees north of the Equator, will see the Sun pass straight overhead at noon. Six months from now the Sun will reach its southern extreme and pass overhead for people on the Tropic of Capricorn, and northerners will experience their shortest days of the year, at the winter solstice. The Sun's angle relative to Earth's equator changes so gradually close to the solstices that, without instruments, the shift is difficult to perceive for about 10 days. This is the origin of the word solstice, which means 'solar standstill.' This slow shift means that daylight on June 20 is only about 2 seconds longer than on June 21, at mid-northern latitudes in the United States. It will be about a week before there's more than a minute change to the calculated amount of daylight. Even that's an approximation — Earth's atmosphere bends light over the horizon by different amounts depending on weather, which can introduce changes of more than a minute to sunrise and sunset times. Monuments at Stonehenge in England, Karnak in Egypt, and Chankillo in Peru reveal that people around the world have taken note of the Sun's northern and southern travels for more than 5,000 years. From Stonehenge's circle of standing stones, the Sun will rise directly over an ancient avenue leading away to the northeast on the solstice. We know little about the people who built Stonehenge, or why they went to such great effort to construct it — moving multi-ton stones from rock outcrops as far as 140 miles away. All this to mark the spot on the horizon where the Sun returns each year to rest for a while before moving south again. Perhaps they, like us, celebrated this signal of the coming change of seasons. Leer en español.
Yahoo
4 days ago
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data